Receptor mechanisms of antipsychotic drug action in bipolar disorder – focus on asenapine

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 6, 2011, Pages 197-204

  Reynolds, Gavin p ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BINDING AFFINITY; BIPOLAR DISORDER; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; MANIA; OBESITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PUBLICATION; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 84997930594     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311430112     Document Type: Article

References (47)

1. Agid O. Mamo D. Ginovart N. Vitcu I. Wilson A. Zipursky R. et al. (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209–1215.
2. Alonso J. Angermeyer M. Bernert S. Bruffaerts R. Brugha T. Bryson H. et al. (2004) Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl (420): 55–64.
3. Alvarez P. Pahissa J. (2010) QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 5: 97–104.
4. Audinot V. Newman-Tancredi A. Cussac D. Millan M. (2001) Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors. Neuropsychopharmacology 25: 410–422.
5. Bagdy G. (1996) Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res 73: 277–280.
6. Blier P. Szabo S. (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 66 Suppl 8: 30–40.
7. Chapel S. Hutmacher M. Haig G. Bockbrader H. de Greef R. Preskorn S. et al. (2009) Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 49: 1297–1308.
8. Chen C. Huang M. Lu M. (2007) Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacol 27: 516–517.
9. Choi Y. Wong E. Henry B. Shahid M. Tarazi F. (2010) Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 13: 405–410.
10. Cipriani A. Barbui C. Salanti G. Rendell J. Brown R. Stockton S. et al. (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378: 1306–1315.
11. Citrome L. (2009) Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 63: 1762–1784.
12. Creed-Carson M. Oraha A. Nobrega J. (2011) Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 219: 273–279.
13. Ejsing T. Pedersen A. Linnet K. (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol 20: 493–500.
14. Ghanbari R. El Mansari M. Shahid M. Blier P. (2009) Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol 19: 177–187.
15. Goodwin G. and Consensus Group of the British Association for Psychopharmacology (2009) Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23: 346–388.
16. Haddad P. Sharma S. (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911–936.
17. Haddad P. Wieck A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291–2314.
18. Halbreich U. Rojansky N. Palter S. Hreshchyshyn M. Kreeger J. Bakhai Y. et al. (1995) Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57: 485–491.
19. Hedlund P. (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206: 345–354.
20. Henry C. M'bailara K. Desage A. Antoniol B. (2006) Multiplicity of syndromes associating manic and depressive symptoms: the need for a dimensional approach. Encephale 32: 351–355.
21. Herrick-Davis K. Grinde E. Teitler M. (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295: 226–232.
22. Jensen N. Cremers T. Sotty F. (2010) Therapeutic potential of 5-HT2C receptor ligands. ScientificWorldJournal 10: 1870–1885.
23. Kapur S. (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160: 13–23.
24. Kirk S. Neill J. Jones D. Reynolds G. (2004) Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 505: 253–254.
25. Kirk S. Glazebrook J. Grayson B. Neill J. Reynolds G. (2009) Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl) 207: 119–125.
26. Kroeze W. Hufeisen S. Popadak B. Renock S. Steinberg S. Ernsberger P. et al. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519–526.
27. Masopust J. Tuma I. Libiger J. (2008) Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro Endocrinol Lett 29: 435–437.
28. Matsui-Sakata A. Ohtani H. Sawada Y. (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20: 368–378.
29. Mavrikaki M. Nomikos G. Panagis G. (2010) Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania. Int J Neuropsychopharmacol 13: 541–548.
30. McIntyre R. Cohen M. Zhao J. Alphs L. Macek T. Panagides J. (2009) Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11: 815–826.
31. Meaney A. O’Keane V. (2007) Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 93: 136–143.
32. Nelson J. Papakostas G. (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166: 980–991.
33. Newcomer J. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1–93.
34. Ray W. Chung C. Murray K. Hall K. Stein C. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235.
35. Reynolds G. (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18: 340–345.
36. Reynolds G. Hill M. Kirk S. (2006) The 5-HT2C receptor and antipsychotic-induced weight gain - mechanisms and genetics. J Psychopharmacol 20: 15–18.
37. Reynolds G. Kirk S. (2010) Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther 125: 169–179.
38. Scheepers F. Gespen de Wied C. Kahn R. (2001) The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol 21: 575–582.
39. Shahid M. Walker G. Zorn S. Wong E. (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23: 65–73.
40. Snigdha S. Thumbi C. Reynolds G. Neill J. (2008) Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 22: 567–571.
41. Szegedi A. Zhao J. van Willigenburg A. Nations K. Mackle M. Panagides J. (2011) Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 11: 101.
42. Tarazi F. Zhang K. Baldessarini R. (2002) Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 161: 263–270.
43. Tarazi F. Moran-Gates T. Wong E. Henry B. Shahid M. (2010) Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 24: 341–348.
44. Tohen M. Vieta E. (2009) Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 11 Suppl 2: 45–54.
45. van Os J. (2009) A salience dysregulation syndrome. Br J Psychiatry 194: 101–103.
46. Wesolowska A. (2010) Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep 62: 564–577.
47. Yap Y. Camm A. (2003) Drug induced QT prolongation and torsades de pointes. Heart 89: 1363–1372.